Changchun High-tech's subsidiary's clinical trial application for the trivalent influenza virus split vaccine (BK-01 adjuvant) has been approved
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, Changchun Gaoxin announced that its subsidiary BCHT received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for its trivalent influenza virus split vaccine (BK-01 adjuvant), agreeing to conduct clinical trials for the prevention of influenza caused by related types of influenza viruses
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments